



ophthalmology
futures forums

Virtual2021

ASIAN FORUM

Fri. 26 March



Asian Forum Programme
Virtual 2021



Imagine Your Happiness

Vision, a window to the world.
With vision, we connect with others.
With vision, we feel happiness.

That is why we at Santen believe
seeing is integral to life.
As a company focused on vision,
we explore and grow the unlimited potential
of our ability to see.
Because we know we can one day
achieve a world free of vision problems.
Because we know we can one day
create a future full of smiles
where everyone's vision is nurtured.
Until then, we will not stop challenging ourselves.

Santen

Imagine Your Happiness

CONTENTS:

ASIAN PROGRAMME

Welcome	3
Timings	4
Speakers	
Presenting companies Pannelists Chairs	6
Our sponsors	7
Platinum	8
Gold	9
Silver	10
Bronze	11
New innovator	13
Save the date 2021	14
Programme committee	15



WELCOME: ASIAN VIRTUAL FORUM

Dear colleagues,

Welcome to Ophthalmology Futures (OF) Asian Forum 2021. While we will miss getting together in person, the virtual format allows for opportunities to reach a wider audience and hear from speakers who otherwise would not have been able to be attend. Each forum has a unique theme while maintaining our commitment to bringing together all stakeholders in the advancement of eye care. Our format involves showcasing companies at various stages of the innovation process and we are delighted to have the opportunity to highlight topics that are relevant to eye care in Asia.

Topics for panel sessions will address the latest trends and controversies in cataract and refractive surgery, hot topics pertaining to glaucoma and corneal disease as well the challenges and opportunities specific to the practice and business of ophthalmology in Asia. We will hear from investors as well as corporate

leaders based in Asia, as well as others who make decisions impacting this region of the world.


As always, we would like to thank our advisory board, programme committee, corporate presenters, sponsors and eminent faculty for their invaluable support and assistance without which this meeting would not be possible. Our sponsors have made it possible to offer this meeting free of charge to all attendees for which we are particularly grateful.

Thank you for joining us for Ophthalmology Futures Asia Forum 2021!

Keith Barton and Kuldev Singh
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.
Registered in England No: 8125858.



TIMINGS:

ASIAN VIRTUAL FORUM

08:00 - 08:10

WELCOME FROM THE CO-CHAIRS

Co-chairs

- Keith Barton
- Kuldv Singh

08:10 - 08:20

MARKET OVERVIEW

- Seth Damergy

08:20 - 08:50

PANEL 1: WILL ICLS BRING A SMILE TO REFRACTIVE SURGEONS IN ASIA?

Chair

- Jodhbir Singh Mehta

Panellists

- Karl Stonecipher
- Marcus Ang
- Maximilian Foerst
- Rex Chandler

08:50 - 09:50

COMPANY PRESENTATIONS 1

- **2Eyes Vision S.L**
Susana Marcos
- **Pleryon Therapeutics**
Yu Yu
- **LENSAR, Inc**
Nick Curtis
- **Eye-Yon Medical**
Nahum Ferera
- **TECLens, LLC.**
Patrick Lopath
- **CorNeat Vision**
Almog Aley-Raz

09:50 - 10:20

PANEL 2: HOW WILL CORNEAL ENDOTHELIAL TRANSPLANTATION CHANGE EYE BANK COST AND REVENUE MODELS?

Chair

- Shigeru Kinoshita

Panellists

- Bernie Iliakis
- Gerard Sutton
- Karl Stonecipher
- Namrata Sharma

10:20 - 10:40

INTERVIEW WITH SHIGEO TANIUCHI, PRESIDENT & CEO, SANTEN PHARMACEUTICAL CO. LTD

- Shigeo Taniuchi
- Kuldev Singh

10:40 - 10:50

SPONSOR SHOWCASE

10:50 - 11:20

PANEL 3: CAN ASIA REVERSE THE GLOBAL FEMTO BUST?

Co-chairs

- David Chang
- Soon-Phaik Chee

Panellists

- Michael Lawless
- Nick Curtis
- Rengaraj Venkatesh
- Ronald Yeoh
- Zheng Wang

11:20 - 11:50

PANEL 4: AN ASIAN LEADERSHIP PERSPECTIVE - HOW HAS BUSINESS CHANGED AFTER COVID?

Chair

- James Mazzo

Panellists

- Akiteru Furukawa
- Andy Chang
- David Endicott
- Shervin Korangy
- Warren Foust

11:50 - 13:00

COMPANY PRESENTATIONS 2

- **Avellino Labs**
Eric Bernabei
- **Photon Therapeutics Ltd.**
Sunil Shah
- **Premark Pharma**
Ian Vessey
- **Medtechnoskorp Ltd.**
Rupert Mok
- **LensGen**
Sumit Garg

13:00 - 13:30

PANEL 5: INVESTMENT OPPORTUNITIES IN OPHTHALMOLOGY IN ASIA

Chair

- Amit Kakar

Panellists

- Akiteru Furukawa
- Aman Gandhi
- Da Lui
- Dianna Qian
- Eddie Wang
- Malcolm Ngiam

13:30 - 14:30

COMPANY PRESENTATIONS 3

- **Radiance Therapeutics**
Abigail Mackrill
- **EyeTechCare**
Dietrich Wolf
- **BioLight Life Sciences Ltd.**
Yaacov Michlin
- **Wolfcreek Biotech Pte Ltd.**
Cherry Khoo
- **Equinox Ophthalmic, Inc.**
John Berdahl
- **BELKIN Laser**
Daria Lemann Blumenthal

14:30 - 15:00

PANEL 6: NAVIGATING IP MANAGEMENT CHALLENGES IN ASIA

Chair

- Jonathan Crowston

Panellists

- Alex Jin
- Dietrich Wolf
- Sara Kerrane
- Tae-Woong Koo
- Tony Yeo

15:00 - 15:30

PANEL 7: COST & QUALITY IN MEETING THE CATARACT BACKLOG: PRIVATE VS PUBLIC SECTOR APPROACHES

Chair

- Boris Malyugin

Panellists

- Robert Ang
- Sanduk Ruit
- Sunil Shah
- Tjahjono Gondhowiardjo

15:30 - 16:00

PANEL 8: MIGS FOR ANGLE CLOSURE: THE NEXT HORIZON?

Co-chairs

- Chelvin Sng
- Keith Barton

Panellists

- Brett Trauthen
- Dexter Leung
- Greg Kunst
- Ningli Wang
- Paul Healey
- Victor Chan

16:00 - 16:10


SUMMARY & CONCLUDING REMARKS

Co-chairs

- Keith Barton
- Kuldev Singh



VISUAL FREEDOM IN ONE EXCEPTIONAL LENS



Visian Toric ICL provides outstanding refractive outcomes in patients with myopia and astigmatism¹.

The Visian Toric ICL clinical trial reported¹:

- **98.4%** of patients would have the Visian Toric ICL procedure again
- Predictable outcomes realized across a broad range of treatment options
- **93.8%** of eyes maintained or gained 1 or more lines of BSCVA
- Rapid and stable achievement of outstanding MRSE and MRCyl
- In eyes with pre-op BSCVA 20/20 or better **100%** of eyes obtained **20/40** or better UCVA
- Over **94%** of eyes maintained rotational stability of **≤5°** at all post-op time points

1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014

SPEAKERS: PRESENTING COMPANIES PANNELISTS & CHAIRS

CHAIRS & PANELLISTS

A

- **Akiteru Furukawa**
GM, Corporate Venture Capital group, HOYA Corporation
- **Alex Jin**
Legal Director Patent, Johnson & Johnson Medical (Shanghai) Ltd.
- **Aman Gandhi**
Principal, Kedaara Capital
- **Amit Kakar**
Senior Partner, Head of Novo Holdings Asia
- **Andrew Chang**
Global Head, Sales Ophthalmic Device & President, Zeiss

B

- **Bernie Iliakis**
COO, CorneaGen
- **Bobby Ang**
Senior Consultant Asian Eye Institute
- **Boris Malyugin**
Dty Director General (R&D, Edu), Department Chief, S. Fyodorov Eye Microsurgery Federal State Institution
- **Brett Trauthen**
CSO, Ivantis

C

- **Chelvin Sng**
Associate Professor, National University of Singapore. Senior Consultant, National University Hospital, Singapore

D

- **David Chang**
Clinical Professor, University of California, San Francisco-Private practice, Los Altos, California, USA
- **David Endicott**
CEO, Alcon
- **Dexter Leung**
Clinical Associate Professor (Hon), Dept of Ophthalmology & Visual Sciences, Chinese University of Hong Kong / Consultant Ophthalmologist, HK Sanatorium & Hospital
- **Dianna Qian**
Partner, Pivotal Bioventure
- **Dietrich Wolf**
CEO, EYE TECH CARE

E

- **Eddie Wang**
Co-founder & COO, Rimongi

G

- **Gerard Sutton**
Professor, Corneal & Refractive Surgery, University of Sydney, Australia
- **Greg Kunst**
VP, Global Marketing, Glaukos

J

- **James Mazzo**
CEO, Avellino, exec Chair Neurotech. Adviser, Zeiss & Adviser Bain
- **Jodhbir Singh Mehta**
Head & Senior Consultant Cornea & External Eye Diseases Department Singapore National Eye Centre
- **Jonathan Crowston**
Professor of Ophthalmology, Director, Centre for Vision Research, Duke-NUS Medical School, Glaucoma Consultant, Singapore National Eye Centre & Singapore Eye Research Institute

K

- **Karl Stonecipher**
Clinical Associate Professor of Ophthalmology, University of North Carolina, USA
- **Keith Barton**
Consultant, Moorfields Eye Hospital, London, UK. Co-founder, Ophthalmology Futures Forums
- **Kuldev Singh**
Professor of Ophthalmology & Director, Glaucoma Service, Stanford University School of Medicine. Co-founder, Ophthalmology Futures Forums

L

- **Lui Da**
Managing Director, CR-CP Life Science Fund

M

- **Malcolm Ngiam**
Deputy Managing Director, Essex Bio-Technology Ltd.
- **Marcus Ang**
Senior Consultant Ophthalmologist, Cornea & Refractive Service, Singapore National Eye Center, Associate Professor, DUKE-NUS, Department of Ophthalmology & Visual Sciences, Singapore
- **Maximilian Foerst**
President Greater China, Carl Zeiss (Shanghai Co., Ltd.)
- **Michael Lawless**
Ophthalmic Surgeon, Vision Eye Institute, Sydney. Member Medical Advisory Board, Vision Eye Institute. Clinical Associate Professor, University of Sydney

N

- **Namrata Sharma**
Professor of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences
- **Nick Curtis**
CEO, LENSAR, Inc.
- **Ningli Wang**
Director, Beijing Tongren Eye Center

P

- **Paul Healey**
Professor of Ophthalmology, University of Sydney, Westmead & Sydney Eye Hospitals, Sydney, Australia

R

- **Rengaraj Venkatesh**
CMO, Aravind Eye Care System Pondicherry
- **Rex Chandler**
VP, Global Strategic Marketing STAAR Surgical Company
- **Ronald Yeoh**
Clinical Associate Professor, Singapore National Eye Centre, Duke-NUS Graduate Medical School, Singapore

S

- **Sanduk Ruit**
Executive Director, Tilganga Institute of Ophthalmology
- **Sara Kerrane**
VP, Intellectual Property, Litigation & Regulatory Counsel
- **Seth Damergy**
Managing Director, Head of Medical Technology, UBS Investment Bank. Healthcare Investment Banking Group
- **Shervin Korangy**
President & CEO, BVI Medical
- **Shigeo Taniuchi**
President & CEO, Santen Pharmaceutical Co. Ltd
- **Shigeru Kinoshita**
Professor & Chair, Department of Frontier Medical Science & Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
- **Soon Phaik Chee**
Senior Consultant, Singapore National Eye Centre, Singapore
- **Sunil Shah**
Consultant Ophthalmologist

T

- **Tae-Woong Koo**
Partner, Morgan, Lewis & Bockius LLP
- **Tjahjono D. Gondhowiardjo**
Director, Development & Education JEC Eye Hospitals & Clinic
- **Tony Yeo**
Managing Director, Intellectual Property Drew & Napier LLC

V

- **Victor Chan**
Head of Marketing & Sales, Surgical Device, Santen Inc.

W

- **Warren Foust**
Worldwide President, Johnson & Johnson Surgical Vision

Z

- **Zheng Wang**
CMO, Refractive Surgery, Aier Group

PRESENTING COMPANIES

#

- **2Eyes Vision S.L**
Susana Marcos
Co-founder

A

- **Avellino Labs**
Eric Bernabei
Global Head of Corporate & Business Development

B

- **BELKIN Laser**
Daria Lemann-Blumenthal, CEO
- **BioLight Life Sciences Ltd.**
Yaacov Michlin
CEO

C

- **CorNeat Vision**
Almog Aley-Raz
CEO

E

- **Equinox Ophthalmic, Inc.**
John Berdahl
CMO
- **EYE TECH CARE**
Dietrich Wolf
CEO
- **Eye-Yon Medical**
Nahum Ferera
CEO

L

- **LENSAR, Inc.**
Nick Curtis
CEO
- **LensGen**
Sumit Garg
Medical Director

M

- **Medtechnoskorp Ltd.**
Rupert Mok
CEO

P

- **Photon Therapeutics Ltd.**
Sunil Shah
Consultant Ophthalmologist
- **Pleryon Therapeutics**
Yu Yu
CEO
- **Premark Pharma**
Ian Vessey
Managing Director

R

- **Radiance Therapeutics**
Abigail Mackrill
Director of Business Development

T

- **TECLens, LLC**
Patrick Lopath
COO

W

- **Wolfcreek Biotech Pte Ltd.**
Cherry Khoo
Managing Director

ALL OF THE SPEAKERS FOR THE ASIAN RETINA AND ASIAN FORUMS CAN BE FOUND ON OUR WEBSITE:

[OPHTHALMOLOGY-FUTURES.COM/FORUMS](https://ophthalmology-futures.com/forums)



SPONSORS: ASIAN FORUMS 2021

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.

PLATINUM



GOLD



SILVER



BRONZE



NEW INNOVATORS



PLATINUM

Alcon

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 70 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

For more information, please visit www.alcon.com

Santen

As a global specialized company dedicated exclusively to ophthalmology, Santen brings 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide, Santen continues to grow its global presence across Asia, Europe, and North America, providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and infection to patients around the world.

For more information, please visit www.santen.com



GOLD



STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL", which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

For more information, please visit the Company's website at www.staar.com

Helping Doctors Improve Their Patients' Quality of Life.

ZEISS Medical Technology Business Group



Improving Quality of Life

ZEISS Medical Technology is proud to support the **Ophthalmology Futures Asian Forum**

www.zeiss.com

SILVER

ESSILOR

SEEING THE WORLD BETTER

Essilor International is the world's leading ophthalmic optics company. For 170 years the Essilor Group has put its expertise at the service of good vision in designing, manufacturing and distributing quality products and services to eyecare professionals but also via innovative business models. Essilor provides solutions to correct and protect the visual health of the 7.7 billion people in the world as part of its mission "improving lives by improving sight". A pioneer, innovation continuously drives Essilor growth, with more than €200 million each year dedicated to research and development. Essilor Group's flagship brands include Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant® and Bolon™. At Essilor we believe that people deserve the right vision solutions to unleash the full potential of their life, every day, all life long. That belief is anchored in the Group's mission.

For more information, please visit www.essilor.com



REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

Please visit www.regenxbio.com



Seeing beyond

The Medical Technology segment of ZEISS offers complete solutions to diagnose and treat ophthalmic diseases. With a special focus on ophthalmology and ophthalmic surgery, the company supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.

For more information, please visit www.zeiss.com/meditec/int/about-us.html

BRONZE



GenSight Biologics is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.

Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.

Our second lead product candidate, GS030, combines gene therapy with optogenetics and is currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).

For more information, please visit www.gensight-biologics.com



Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

For more information on the Company, please visit www.ivericbio.com



LENSAR
CATARACT LASER WITH AUGMENTED REALITY

LENSAR®, Inc., the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline® IV. This includes enhancements unique to LENSAR that are dedicated to help surgeons confidently manage astigmatism and optimize patient outcomes, for both toric IOLs and arcuate incisions.

Enhancements include IntelliAxis Refractive Capsulorhexis®, which incorporates lenticular markings to guide precise and confident toric IOL alignment, and wireless transfer of preoperative data from multiple devices, for seamless treatment planning. Iris registration further contributes to accuracy by automatically accounting for cyclotorsion. The LENSAR Laser is revolutionizing the surgeon's ability to deliver great outcomes for astigmatic patients.

Please visit www.lensar.com



Ora is the world's leading full-service ophthalmic research organization with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients earn 48 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's unique models, methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts to maximize the value of new product initiatives.

For more information, please visit www.oraclinical.com

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Our gene therapy product candidates are aligned to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.

Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene

therapy programs using our NAV® Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.

We are developing RGX-314 as a potential one-time gene therapy treatment for wet AMD, diabetic retinopathy and other additional chronic retinal conditions treated with anti-VEGF.



We believe that people's sight matters. Our organisational strategy is built around that core belief and our purpose - to support Moorfields to discover, develop and deliver the best eye care.

www.moorfieldseyecharity.org.uk



We campaign to raise awareness so glaucoma is detected early and can be treated, we support people to live well with glaucoma and we fund sight saving research.



www.glaucoma.uk

NEW INNOVATORS



LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia. With its innovative Juvene® IOL the company aims to bring to market this revolutionary device designed to restore full range of vision with quality optics and improved safety due to the modular, capsule filling design. The company is currently progressing through the IDE approval process and is planning a large Series B Financing in early 2021 that will fund the company through approval of the Juvene IOL pivotal FDA study.

For more information about the financing please contact Ramgopal Rao, CEO at rrao@lensgen.com and visit www.lensgen.com



Radiance Therapeutics is developing a next-generation beta therapy device for ophthalmic scar prophylaxis.

This therapeutic modality has been validated in 4 randomised controlled trials from preeminent ophthalmic research teams. Applied topically at the time of surgery, beta therapy has been shown to significantly improve glaucoma filtration surgery outcomes. The most recent of these studies reported odds ratios indicating that beta therapy patients were five and a half times more likely to experience lower IOP at the end of one year than patients treated with antimetabolite mitomycin-C.

For more information, please visit www.radiancetherapeutics.com



Re-Vana Therapeutics based in Northern Ireland and Tampa Florida, is a specialty ocular therapeutic and drug delivery company focused on the development of sustained release biologics and small molecules.

The Re-Vana platforms, which includes EyeLief® and OcuLief® photocrosslinked technologies, can deliver at least 6 months sustained delivery of large molecule biologics, including anti-VEGF therapies. Re-Vana's technology could also spur a new generation of small molecule therapeutics enabling up to 12 months delivery or greater.

For more information, please visit www.revanatx.com



ophthalmology
futures forums

Virtual2021

SAVE THE DATES

EURO VIRTUAL & HYBRID FORUMS

European Forum *HYBRID 2021*

Thurs. 26 August

Retina Forum *Virtual 2021*

Thurs. 09 September

(Forums begin @ 8am CET / GMT +1)



www.ophthalmology-futures.com

PROGRAMME COMMITTEE

Ike Ahmed | Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

Jorge Alio | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visum Corporation, Spain.

Gerd Auffarth | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

Francesco Bandello | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

David Chang | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

Steve Charles | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

Paul Chew | Professor of Ophthalmology, National University of Singapore, Singapore.

Beatrice Cochener | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

Jost Jonas | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

Sir Peng Khaw | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

Shigeru Kinoshita | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

Richard Lindstrom | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

Boris Malyugin | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

Prof David Spalton | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

Prof Dr Ingeborg Stalmans | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

Paulo Eduardo Stanga | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

Paul Rosen | Consultant Ophthalmic Surgeon, Oxford Eye Hospital, Oxford, UK.

José-Alain Sahel | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments

of Ophthalmology, Quinze- Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Julian D. Stevens | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

Donald Tan Tiang Hwee | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

Marie-Jose Tassignon | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

Adnan Tufail | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

Tien Yin Wong | Vice Dean, Academic & Clinical Development, Duke-NUS Medical School, Singapore. Provost's Chair Professor, National University of Singapore. Deputy Group CEO (Research & Education), SingHealth, Singapore. Medical Director & Senior Consultant Ophthalmologist, Singapore National Eye Centre. Chair, Ophthalmology & Visual Sciences Academic Clinical Programme. Chairman, Board of Directors, Singapore Eye Research Institute, Singapore.

ADVISORS

Laurent Attias | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

Eugene de Juan | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

Tom Dunlap | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

Malvina Eydelman | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

Akira Kurokawa | Chairman. Santen Pharmaceutical Co.

James Mazzo | Avellino, exec Chair Neurotech. Adviser, Zeiss & Adviser Bain.

Naveed Siddiqi | Novo Ventures.

ORGANISING COMMITTEE

Keith Barton | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK.

Don Budenz | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

Lea Pietrolongo | Operational Director, Ophthalmology Futures Forums, UK.

Kuldev Singh | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

Chelvin Sng | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

Sanny Yuzhen Jiang | Honorary Clinical Fellow. Moorfields Eye Hospital. Senior Research Associate, University College London Institute of Ophthalmology, UK.





We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



@AlconEyeCare
@AlconCareers



@Alcon



@AlconLife

